We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




FOXM1 Oncogene Interferes with Stem Cell Differentiation and Promotes Cancer-Like Cell Behavior

By LabMedica International staff writers
Posted on 24 Nov 2010
The role of the FOXM1 oncogene in initiation of cancer-like cell transformations has been defined using a three-dimensional cell culture system.

Investigators at Queen Mary University (London, United Kingdom) worked with cultures of human keratinocytes with stem/progenitor cell properties growing in a functional three-dimensional organotypic epithelial tissue regeneration system. More...
Use of this three-dimensional tissue culture system allowed researchers to perform experiments on manipulated human cells without provoking ethical issues associated with human or animal subjects.

They reported in the November 9, 2010, online edition of the journal Cancer Research that aberrant upregulation of FOXM1 in adult human epithelial stem cells induced a precancer phenotype, a condition similar to human hyperplasia. They showed that excessive expression of FOXM1 exploited the inherent self-renewal proliferation potential of stem cells by interfering with the differentiation pathway, thereby expanding the progenitor cell compartment. It was therefore hypothesized that FOXM1 induced cancer initiation through stem/progenitor cell expansion.

Senior author Dr. Muy-Tek Teh, lecturer in head and neck cancer at Queen Mary University, said, "Now we know that FOXM1 plays a key role in cancer initiation we aim to translate our basic findings into clinically useful molecular diagnostic tests to detect cancer growth at early stages. Furthermore, understanding the origin of cancer initiation may unveil new research opportunities for finding effective antitumor drugs that stop or prevent cancer at its earliest incipient stage.”

Related Links:

Queen Mary University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hematology Consumables
Bioblood Devices
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.